[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100357715":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":62,"collaborators":64,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":23,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":26,"studyType":81,"phases":82,"briefSummary":85,"conditions":86,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Genesis Athens Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group of participants receiving PRP treatment","EXPERIMENTAL","Women presenting with POR, treated with autologous PRP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period.",[13],"Biological: PRP",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group: participants receiving Platelet Free Plasma","PLACEBO_COMPARATOR","Women presenting with POR, treated with autologous PFP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period",[19],"Biological: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","PRP","Autologous PRP intra ovarian infusion",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Autologous PFP intra ovarian infusion",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Mara Simopoulou, PhD","CONTACT","+306979234100","marasimopoulou@hotmail.com",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"Agni Pantou, MD, PhD Candidate","+306974447702","agni.pantou@genesisathens.gr",[42],{"facility":43,"status":44,"city":45,"state":26,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Genesis AC","RECRUITING","Athens","15232","Greece","GR",{"type":50,"coordinates":51},"Point",[52,53],23.72784,37.98376,{"lat":53,"lon":52},[56,57,60],{"name":38,"role":34,"phone":26,"phoneExt":26,"email":40},{"name":58,"role":59,"phone":26,"phoneExt":26,"email":26},"Agni Pantou, MD","PRINCIPAL_INVESTIGATOR",{"name":61,"role":59,"phone":26,"phoneExt":26,"email":26},"Konstantinos Pantos, MD, PhD",{"type":63,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[65],{"name":66,"class":6},"National and Kapodistrian University of Athens","100357715","phase-2-autologous-platelet-rich-plasma-intra-ovarian-infusion-in-poor-responders-100357715",false,"NCT03937661","Autologous Platelet-Rich Plasma Intra-ovarian Infusion in Poor Responders","Investigating Improvement of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in Poor Responders","Inclusion Criteria:\n\n* Poor Ovarian Response according to Bologna Criteria (fulfilling 2 out of 3 of the following)\n* Age ≥ 40 years\n* AMH \\\u003C 1.1 ng\u002Fml OR AFC \\\u003C 7\n* ≤ 3 oocytes with a conventional stimulation protocol)\n* Discontinuation of any complementary\u002Fadjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment.\n* Willing to comply with study requirements\n\nExclusion Criteria:\n\n* Any pathological disorder related to reproductive system anatomy\n* Cycle irregularities\n* Amenorrhea\n* Endometriosis\n* Adenomyosis\n* Fibroids and adhesions\n* Infections in reproductive system\n* Current or previous diagnosis of cancer in reproductive system\n* History of familiar cancer in reproductive system\n* Severe male factor infertility\n* Prior referral for PGT\n* Ovarian inaccessibility -Endocrinological disorders (Hypothalamus-\n* Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)\n* BMI\\>30 kg\u002Fm2 or BMI\\\u003C18.5 kg\u002Fm2\n* Systematic autoimmune disorders",true,"FEMALE","35 Years","47 Years",{"count":79,"type":80},100,"ESTIMATED","INTERVENTIONAL",[83,84],"PHASE2","PHASE3","Autologous PRP intra ovarian infusion may improve ovarian response, patients' hormonal profile as well as fresh embryo transfer (ET)-ICSI cycles' outcome in patients presenting with Poor Ovarian Response (POR).",[87,88],"Ovary; Anomaly","Infertility, Female","2024-12-20",{"date":91,"type":92},"2024-12-27","ACTUAL",{"date":94,"type":92},"2019-05-06",{"date":96,"type":80},"2025-08-30",{"name":5,"class":6},1]